Treatment of Stage D2 Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A®: A Southwest Oncology Group Study-Reference-Cited by-同舟云学术

Treatment of Stage D2 Hormone Refractory Carcinoma of the Prostate with 5-Fluorouracil and Roferon-A®: A Southwest Oncology Group Study

Published:1996-04 Issue:2 Volume:11 Page:119-123
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Marshall M. Ernest,Wolf Michael,O'Rourke Mark,Barnett Teresita C.,Crawford E. David

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.1996.11.119

Reference18 articles.

1. The chemotherapy of urologic cancer

2. Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate

3. Chemotherapy of Advanced Carcinoma of the Prostate with 5-Fluorouracil, Cyclophosphamide and Adriamycin

4. Levamisole as an adjuvant to chemotherapy in extensive bronchogenic carcinoma. A veterans administration lung cancer group study

5. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Yak interferon-alpha loaded solid lipid nanoparticles for controlled release;Research in Veterinary Science;2010-02

2. Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation;American Journal of Health-System Pharmacy;2007-08-15

3. Phase II Trial of Docetaxel/Capecitabine in Hormone-Refractory Prostate Cancer;Clinical Genitourinary Cancer;2006-09

4. Long-term stabilization of recombinant human interferon α 2b in aqueous solution without serum albumin;International Journal of Pharmaceutics;2003-10

5. Hormone-refractory prostate cancer responding to capecitabine;UROLOGY;2003